Six years after his Alzheimer’s diagnosis, 90-year-old Zelik Bocknek (Zel) refuses to slow down — and he believes his active ...

Sleepiness During the Day May Be Tied to Pre-Dementia Syndrome Nov. 6, 2024 — Older people who are sleepy during the day or lack enthusiasm for activities due to sleep issues may be more likely ...

New details have emerged about how Alzheimer’s disease affects the brain. Researchers led by the Allen Institute for Brain Science in Seattle and University of Washington Medicine have ...

Hallucinations are a fairly common symptom in the advanced stages of Alzheimer’s disease. Treatment options like medications or therapy can help reduce their frequency and effect. Alzheimer’s ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.

A multi-institutional study made up of 26 researchers led by the University of Melbourne has discovered that iron-reducing deferiprone accelerates cognitive decline in patients with early ...

Each year, Baylor Medicine's Alzheimer Disease and Memory Disorders Center manages more than 3,000 patient visits. People come to our center for diagnosis of their memory problems, treatment and ...

An 80-something patient came in for an annual visit recently and was worried that recent memory lapses might be symptoms of Alzheimer’s disease. This patient, like several others in my practice ...

Alzheimer's disease damages the brain before any symptoms begin to appear, new research suggests. This is part of a new two-step model of Alzheimer's progression, which features an early "silent ...

Studies have not found evidence that aluminum contributes to Alzheimer’s disease development. But research is ongoing, and you could be a part of it. Alzheimer’s is a progressive disease that ...

Nearly 7 million Americans 65 and older are living with Alzheimer's disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks. LIGHTFIELD STUDIOS ...

By Walt Bogdanich and Carson Kessler By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401. For the drugmaker Eisai, the trial was a ...